Imexpharm PEG
The PEG Ratio (Price/Earnings-to-Growth) of Imexpharm (IMP.VN) as of Sep 10, 2026 is 1.47. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 1.60 — a change of -8.10% (lower).
Get this data via API
Financial Data API
PEG
1.47
YoY
-8.10%
Last updated:
The Imexpharm PEG history
3 Years
10 Years
25 Years
Max
| YEAR | PEG | YoY |
|---|---|---|
| 1.47 | -8.10% | |
| 1.60 | -6.64% | |
| 1.71 | -25.38% | |
| 2.30 | -15.41% | |
| 2.71 | +10.90% | |
| 2.45 | -22.56% | |
| 3.16 | -24.85% | |
| 4.21 | -15.38% | |
| 4.97 | -14.78% | |
| 5.83 | -10.27% | |
| 6.50 | +8.62% | |
| 5.98 | — |
Imexpharm Stock analysis
Frequently Asked Questions about Imexpharm stock
PEG Ratio (Price/Earnings-to-Growth) of Imexpharm is 1.47 in 2026.
PEG Ratio (Price/Earnings-to-Growth) of Imexpharm changed from 1.60 to 1.47, representing a -8.10% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Imexpharm since 2006 – with annual values, charts, and detailed analysis.
The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.
PEG = P/E Ratio / Expected Annual EPS Growth Rate
To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).
A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.
Valuation — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth